OKYO Pharma Limited header image

OKYO Pharma Limited

OKYO

Equity

ISIN GG00BMFG5F62 / Valor 127195533

UTP NYSE Arca (2026-11-10)
USD 1.38+7.81%

OKYO Pharma Limited
UMushroom community rating:

star star star star star
5.00 3 votes No rating yet
NegativeNeutralPositive

About company

OKYO Pharma Limited is a biotechnology company focused on developing therapies for inflammatory dry eye diseases and chronic pain management.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (02.11.2026):

OKYO Pharma Limited — results for the quarter ended March 31, 2023 (Q4 fiscal year 2023 / twelve months ended March 31, 2023): the company reported a wider annual loss driven by higher development spending while continuing clinical advancement of its lead candidate OK-101, including initiation and dosing in its Phase 2 dry eye disease (DED) trial and a planned small trial for neuropathic corneal pain (NCP).

Net loss

OKYO reported a loss of $13.7 million for the twelve months ended March 31, 2023, versus a $6.3 million loss for the twelve months ended March 31, 2022.

Research & development expenses

R&D expenses rose to $6.3 million for the period (12 months ended March 31, 2023) from $1.6 million the prior year, primarily due to IND filing and clinical trial activities for OK-101 in DED.

Cash position

OKYO ended the period with $4.0 million in cash as of March 31, 2023, up from $2.7 million as of March 31, 2022.

Clinical development and near-term milestones

The company activated U.S. sites and initiated dosing in its 240-patient Phase 2, randomized, double-masked, placebo-controlled trial of OK-101 for DED (top-line data expected in Q4 2023). OKYO also announced an agreement with Tufts Medical Center for a planned 40-patient open-label NCP trial, with an IND for NCP planned to be filed in Q4 2023.

Summarized from source with an LLMView Source

Key figures

-48.7%1Y
-19.8%3Y
%5Y

Performance

74.8%1Y
81.8%3Y
99.9%5Y

Volatility

Market cap

50 M

Market cap (USD)

Daily traded volume (Shares)

104,757

Daily traded volume (Shares)

1 day high/low

1.2 / 1.18

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

5.00

3 votes
Performance:
starstarstarstarstar
5.00
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
5.00
Nature:
starstarstarstarstar
5.00
Diana Costa
Switzerland, 24 Mar 2025
star star star star star
Ich bin sehr zufrieden und stolz auf das Unternehmen… weiter so
Diana Costa
Switzerland, 06 Mar 2025
star star star star star
Weiter so 👏🏽 toll … die Augen sind sehr wichtig 👍🏼👍🏼👍🏼👍🏼
Diana Costa
Switzerland, 04 Mar 2025
star star star star star
Wir brauchen solche Unternehmen mehr und mehr.. fertig mit Sicca-Syndrom.

EQUITIES OF THE SAME SECTOR

STERIS PLC
STERIS PLC STERIS PLC Valor: 47027903
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%USD 257.12
Basilea Pharmaceutica Ltd, Allschwil
Basilea Pharmaceutica Ltd, Allschwil Basilea Pharmaceutica Ltd, Allschwil Valor: 1143244
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.39%CHF 71.20
Molina Healthcare Inc
Molina Healthcare Inc Molina Healthcare Inc Valor: 1538184
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.48%USD 206.35
SHL Telemedicine Ltd
SHL Telemedicine Ltd SHL Telemedicine Ltd Valor: 1128957
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%CHF 1.07
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC Jazz Pharmaceuticals PLC Valor: 14769757
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.77%USD 245.43
Smith & Nephew PLC
Smith & Nephew PLC Smith & Nephew PLC Valor: 1111046
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.42%USD 30.92
Addex Therapeutics Ltd
Addex Therapeutics Ltd Addex Therapeutics Ltd Valor: 2985075
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
6.93%CHF 0.022
Fresenius Medical Care AG
Fresenius Medical Care AG Fresenius Medical Care AG Valor: 523134
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.92%USD 22.74
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited Valor: 12029898
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.42%INR 1,905.00
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited Valor: 11500585
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.40%INR 1,017.95